Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafluprost

FDA-approved product (solution/drops, ophthalmic), marketed as Tafluprost, Zioptan.

Registered studies
37
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafluprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafluprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafluprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

    NCT07074782 · start 2026-05

    Registered record
    Registry ID
    NCT07074782
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2026-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins

    NCT05039684 · start 2021-10-01

    Registered record
    Registry ID
    NCT05039684
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-10-01
    Completion
    2025-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

    NCT04828057 · start 2021-09-01

    Registered record
    Registry ID
    NCT04828057
    Conditions
    Ocular Surface Disease; Primary Open Angle Glaucoma
    Interventions
    Tafluprost, timolol maleate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-01
    Completion
    2022-08-24
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Surface Disease; Primary Open Angle Glaucoma
    InterventionTafluprost, timolol maleate
    PhaseNot recorded
    Registry statusCompleted

  • 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.

    NCT05299593 · start 2020-06-04

    Registered record
    Registry ID
    NCT05299593
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    tafluprost/timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06-04
    Completion
    2022-06-30
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    Interventiontafluprost/timolol
    PhasePhase 4
    Registry statusUnknown

  • Alleviating Effects Against High Intraocular Pressure by Oral Intake of Cordyceps Cicadae Mycelia

    NCT05304299 · start 2020-03-10

    Registered record
    Registry ID
    NCT05304299
    Conditions
    Supplement
    Interventions
    Cordyceps Cicadae Mycelia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-03-10
    Completion
    2021-12-31
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSupplement
    InterventionCordyceps Cicadae Mycelia
    PhaseNot applicable
    Registry statusCompleted

  • Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

    NCT04461249 · start 2019-06-01

    Registered record
    Registry ID
    NCT04461249
    Conditions
    Primary Open Angle Glaucoma
    Interventions
    Latanoprost 0.005% Ophthalmic Solution; Travoprost 0.004% ophthalmic solution; Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-06-01
    Completion
    2020-04-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma
    InterventionLatanoprost 0.005% Ophthalmic Solution; Travoprost 0.004% ophthalmic solution; Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
    PhaseNot recorded
    Registry statusCompleted

  • Tafluprost Preservative Free Switch Study

    NCT04654611 · start 2019-02-01

    Registered record
    Registry ID
    NCT04654611
    Conditions
    Glaucoma; Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    preservative free tafluprost 0.0015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2020-02-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Primary Open Angle Glaucoma; Ocular Hypertension
    Interventionpreservative free tafluprost 0.0015%
    PhasePhase 4
    Registry statusCompleted

  • A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

    NCT03822559 · start 2019-01-20

    Registered record
    Registry ID
    NCT03822559
    Conditions
    Open-angle Glaucoma, Ocular Hypertension
    Interventions
    A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL; A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-01-20
    Completion
    2023-04-04
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma, Ocular Hypertension
    InterventionA preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL; A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy

    NCT03595865 · start 2018-08-01

    Registered record
    Registry ID
    NCT03595865
    Conditions
    Glaucoma; Drugs
    Interventions
    tafluprostin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2020-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Drugs
    Interventiontafluprostin
    PhaseNot applicable
    Registry statusUnknown

  • From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy

    NCT04673604 · start 2018-05-06

    Registered record
    Registry ID
    NCT04673604
    Conditions
    Glaucoma; Ocular Surface Disease
    Interventions
    Assessment of ocular surface staining (Oxford score 0-15 scale); mean diurnal intraocular pressure-lowering
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-05-06
    Completion
    2020-06-29
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Surface Disease
    InterventionAssessment of ocular surface staining (Oxford score 0-15 scale); mean diurnal intraocular pressure-lowering
    PhaseNot applicable
    Registry statusCompleted

  • Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

    NCT04737928 · start 2018-04-02

    Registered record
    Registry ID
    NCT04737928
    Conditions
    Glaucoma, Primary Open Angle
    Interventions
    Latanoprost; tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-04-02
    Completion
    2019-01-22
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Primary Open Angle
    InterventionLatanoprost; tafluprost
    PhaseNot applicable
    Registry statusCompleted

  • Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma

    NCT04455126 · start 2018-04-01

    Registered record
    Registry ID
    NCT04455126
    Conditions
    Glaucoma
    Interventions
    Preservative-free tafluprost eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-04-01
    Completion
    2020-06-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionPreservative-free tafluprost eye drops
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

    NCT03612817 · start 2017-01

    Registered record
    Registry ID
    NCT03612817
    Conditions
    Glaucoma, Open-Angle
    Interventions
    Tafluprost/timolol fixed combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2018-07
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle
    InterventionTafluprost/timolol fixed combination
    PhasePhase 4
    Registry statusCompleted

  • RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.

    NCT03292796 · start 2016-12-07

    Registered record
    Registry ID
    NCT03292796
    Conditions
    Open Angle Glaucoma and Cataract
    Interventions
    Prostaglandins
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-07
    Completion
    2020-07-25
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma and Cataract
    InterventionProstaglandins
    PhasePhase 2
    Registry statusCompleted

  • A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness

    NCT03204487 · start 2016-05-10

    Registered record
    Registry ID
    NCT03204487
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Tafluprost 15µg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05-10
    Completion
    2017-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionTafluprost 15µg/ml
    PhasePhase 4
    Registry statusCompleted